Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥1.76T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥24.4bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥12.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥27.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥15.4bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥27.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥18.7bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥18.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥13.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥18.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥13.3bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.30Tat 2022-12-31Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.29Tat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥891.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥412.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥419.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥169.8bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥208.462022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.022021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥170.6bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥30.1bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥140.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.5bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.69T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.65T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥38.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥20.3bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥25.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.96T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.76T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥205.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥24.3bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥136.4bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥29.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥107.0bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥20m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.6bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥1.62T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.58T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥40.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥7.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥9.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥24.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥1.86T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥171.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥12.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 354
ItemContextValueUnit
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場名古屋証券取引所プレミア市場札幌証券取引所
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese) 単元株式数は 100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Voting rights (text)FilingDateInstantText · Plus
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember
Original text (Japanese)単元株式数は100株であります。
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember
Original text (Japanese)同上
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember-
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)㈱スズケン
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)名古屋市東区東片端町8番地
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Notes changes in scope of consolidation or equity method (text)CurrentYTDDurationText · Plus
Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes changes in presentation consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes changes in accounting estimates quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes additional information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes regarding promissory notes due on balance sheet date (text)CurrentQuarterInstantText · Plus
Description of fact that quarterly statement of cash flows has not been prepared (text)CurrentYTDDurationText · Plus
Notes regarding dividend (text)Prior1YTDDurationText · Plus
Notes regarding dividend (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus
Notes segment information etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text)Prior1YTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)Prior1YTDDurationText · Plus
Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text)CurrentYTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)CurrentYTDDurationText · Plus
Notes revenue recognition quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass